

# Pre-operative chemotherapy for cancer of the oesophagus

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/02/2010	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr James Lyddiard

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
OE02

## Study information

**Scientific Title**

### Study objectives

To investigate in patients considered to have resectable cancer of the oesophagus whether pre-operative chemotherapy:

1. Prolongs survival
2. Affects physical well-being

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Cancer

**Interventions**

1. One group receives pre-operative chemotherapy followed by surgery
2. The other group = Control group receives surgery alone

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Survival time

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

30/06/1998

**Eligibility****Key inclusion criteria**

1. Tumour considered resectable
2. No evidence of cervical lymph node involvement or metastases
3. Creatinine clearance  $\geq 60$  ml/min
4. Total white blood cell count  $\geq 3.5 \times 10^9$ l
5. Platelet count  $\geq 100 \times 10^9$ l

6. No indication for urgent resection
7. No previous chemotherapy, radiotherapy or surgery for current oesophageal cancer
8. No other previous or concomitant malignant disease

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/02/1992

**Date of final enrolment**

30/06/1998

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

**Sponsor information****Organisation**

Medical Research Council (MRC) (UK)

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (MRC) (UK)

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	long term results	20/10/2009		Yes	No